Cargando…
Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies
Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a dominant trigger of inflammation: human serum factor H-related protein FHR1. In vitro, this protein selectively binds to n...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609651/ https://www.ncbi.nlm.nih.gov/pubmed/31273197 http://dx.doi.org/10.1038/s41467-019-10766-0 |
_version_ | 1783432352679067648 |
---|---|
author | Irmscher, Sarah Brix, Silke R. Zipfel, Svante L. H. Halder, Luke D. Mutlutürk, Sibel Wulf, Sonia Girdauskas, Evaldas Reichenspurner, Hermann Stahl, Rolf A. K. Jungnickel, Berit Wiech, Thorsten Zipfel, Peter F. Skerka, Christine |
author_facet | Irmscher, Sarah Brix, Silke R. Zipfel, Svante L. H. Halder, Luke D. Mutlutürk, Sibel Wulf, Sonia Girdauskas, Evaldas Reichenspurner, Hermann Stahl, Rolf A. K. Jungnickel, Berit Wiech, Thorsten Zipfel, Peter F. Skerka, Christine |
author_sort | Irmscher, Sarah |
collection | PubMed |
description | Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a dominant trigger of inflammation: human serum factor H-related protein FHR1. In vitro, this protein selectively binds to necrotic cells via its N-terminus; in addition, it binds near necrotic glomerular sites of AAV patients and necrotic areas in atherosclerotic plaques. FHR1, but not factor H, FHR2 or FHR3 strongly induces inflammasome NLRP3 in blood-derived human monocytes, which subsequently secrete IL-1β, TNFα, IL-18 and IL-6. FHR1 triggers the phospholipase C-pathway via the G-protein coupled receptor EMR2 independent of complement. Moreover, FHR1 concentrations of AAV patients negatively correlate with glomerular filtration rates and associate with the levels of inflammation and progressive disease. These data highlight an unexpected role for FHR1 during sterile inflammation, may explain why FHR1-deficiency protects against certain diseases, and identifies potential targets for treatment of auto-inflammatory diseases. |
format | Online Article Text |
id | pubmed-6609651 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-66096512019-07-08 Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies Irmscher, Sarah Brix, Silke R. Zipfel, Svante L. H. Halder, Luke D. Mutlutürk, Sibel Wulf, Sonia Girdauskas, Evaldas Reichenspurner, Hermann Stahl, Rolf A. K. Jungnickel, Berit Wiech, Thorsten Zipfel, Peter F. Skerka, Christine Nat Commun Article Persistent inflammation is a hallmark of many human diseases, including anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and atherosclerosis. Here, we describe a dominant trigger of inflammation: human serum factor H-related protein FHR1. In vitro, this protein selectively binds to necrotic cells via its N-terminus; in addition, it binds near necrotic glomerular sites of AAV patients and necrotic areas in atherosclerotic plaques. FHR1, but not factor H, FHR2 or FHR3 strongly induces inflammasome NLRP3 in blood-derived human monocytes, which subsequently secrete IL-1β, TNFα, IL-18 and IL-6. FHR1 triggers the phospholipase C-pathway via the G-protein coupled receptor EMR2 independent of complement. Moreover, FHR1 concentrations of AAV patients negatively correlate with glomerular filtration rates and associate with the levels of inflammation and progressive disease. These data highlight an unexpected role for FHR1 during sterile inflammation, may explain why FHR1-deficiency protects against certain diseases, and identifies potential targets for treatment of auto-inflammatory diseases. Nature Publishing Group UK 2019-07-04 /pmc/articles/PMC6609651/ /pubmed/31273197 http://dx.doi.org/10.1038/s41467-019-10766-0 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Irmscher, Sarah Brix, Silke R. Zipfel, Svante L. H. Halder, Luke D. Mutlutürk, Sibel Wulf, Sonia Girdauskas, Evaldas Reichenspurner, Hermann Stahl, Rolf A. K. Jungnickel, Berit Wiech, Thorsten Zipfel, Peter F. Skerka, Christine Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title | Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title_full | Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title_fullStr | Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title_full_unstemmed | Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title_short | Serum FHR1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
title_sort | serum fhr1 binding to necrotic-type cells activates monocytic inflammasome and marks necrotic sites in vasculopathies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609651/ https://www.ncbi.nlm.nih.gov/pubmed/31273197 http://dx.doi.org/10.1038/s41467-019-10766-0 |
work_keys_str_mv | AT irmschersarah serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT brixsilker serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT zipfelsvantelh serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT halderluked serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT mutluturksibel serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT wulfsonia serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT girdauskasevaldas serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT reichenspurnerhermann serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT stahlrolfak serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT jungnickelberit serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT wiechthorsten serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT zipfelpeterf serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies AT skerkachristine serumfhr1bindingtonecrotictypecellsactivatesmonocyticinflammasomeandmarksnecroticsitesinvasculopathies |